HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Inter Parfums’s Q1 Sales Up 26% In ‘Robust Environment’ For Fragrance

Executive Summary

The New York-based manufacturer of prestige perfumes and cosmetics is “extremely optimistic” about fiscal 2022 and the years ahead, recording net sales growth of 26% in the first quarter, led by major brand innovations, and projecting an 11% increase for the full year.

You may also be interested in...



Sensegen Aims To Put Natural Back In Fragrance With Next-Gen, Sustainable Biotech Solutions

California-based fragrance and flavor developer Sensegen is preparing a formal launch of biotech-based aromas and other fragrance ingredients this summer, touting them as building blocks for category-leading “new naturals” that balance sustainability with quality and value.

US Interim Funding Bill Gets Biden’s Signature; Window Narrows For Cosmetics, Dietary Supplement Legislation

Passed by the US House and signed into law on 30 September, the Continuing Appropriations and Ukraine Supplemental Appropriations Act, 2023, avoids a partial government shutdown and furloughs in FDA user-fee programs. Policy riders stripped from the legislation, including for cosmetics and dietary supplement regulatory changes, could still find their way into a final FY 2023 spending omnibus.

US Interim Funding Bill Gets President Biden’s Signature; Window Narrows For IVD Reg Reform

Passed by the US House and signed into law on 30 September, the Continuing Appropriations and Ukraine Supplemental Appropriations Act, 2023, avoids a partial government shutdown and furloughs in FDA user-fee programs including MDUFA. Policy riders stripped from the legislation, including for FDA oversight of lab-developed tests, could still find their way into a final FY 2023 spending omnibus.

Topics

Latest News
See All
UsernamePublicRestriction

Register

RS152456

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel